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Abstract
Background: Clinical trials where cancer patients were treated with protease inhibitors have suggested that the
serine protease, prostasin, may act as a tumour suppressor. Prostasin is proteolytically activated by the serine
protease, matriptase, which has a very high oncogenic potential. Prostasin is inhibited by protease nexin-1 (PN-
1) and the two isoforms encoded by the mRNA splice variants of hepatocyte growth factor activator inhibitor-1 (HAI-
1), HAI-1A, and HAI-1B.
Methods: Using quantitative RT-PCR, we have determined the mRNA levels for prostasin and PN-1 in colorectal
cancer tissue (n = 116), severe dysplasia (n = 13), mild/moderate dysplasia (n = 93), and in normal tissue from the
same individuals. In addition, corresponding tissues were examined from healthy volunteers (n = 23). A part of
the cohort was further analysed for the mRNA levels of the two variants of HAI-1, here denoted HAI-1A and HAI-
1B. mRNA levels were normalised to β-actin. Immunohistochemical analysis of prostasin and HAI-1 was
performed on normal and cancer tissue.
Results: The mRNA level of prostasin was slightly but significantly decreased in both mild/moderate dysplasia (p
< 0.001) and severe dysplasia (p < 0.01) and in carcinomas (p < 0.05) compared to normal tissue from the same
individual. The mRNA level of PN-1 was more that two-fold elevated in colorectal cancer tissue as compared to
healthy individuals (p < 0.001) and elevated in both mild/moderate dysplasia (p < 0.01), severe dysplasia (p < 0.05)
and in colorectal cancer tissue (p < 0.001) as compared to normal tissue from the same individual. The mRNA
levels of HAI-1A and HAI-1B mRNAs showed the same patterns of expression. Immunohistochemistry showed that
prostasin is located mainly on the apical plasma membrane in normal colorectal tissue. A large variation was found
in the degree of polarization of prostasin in colorectal cancer tissue.
Conclusion: These results show that the mRNA level of PN-1 is significantly elevated in colorectal cancer tissue.
Future studies are required to clarify whether down-regulation of prostasin activity via up regulation of PN-1 is
causing the malignant progression or if it is a consequence of it.
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Background
Extracellular proteases and protease inhibitors are
believed to play an important role during carcinogenesis
in many different ways such as degrading the extracellular
matrix in order to facilitate invasive growth and activating
signal molecules. In accordance with this, proteases were
mostly thought of as promoters of carcinogenesis. How-
ever, clinical trials where cancer patients were treated with
broad-range protease inhibitors have shown that pro-
teases can act as tumour suppressors [1]. Studies using
loss-of-function animal models have further confirmed
the existence of extra-cellular proteases with anti-tumour
properties [2-4]. Prostasin is a relatively unknown extra-
cellular serine protease suspected to play a role as tumour
suppressor [1].
Prostasin is a glycosylphosphatidylinositol (GPI)-
anchored trypsin-like protease expressed in most epithe-
lial cells [5,6]. It is to some degree shed from the mem-
brane and found as a soluble enzyme [7]. The
proteolytical activity of prostasin can be inhibited by pro-
tease nexin-1 (PN-1) [8,9] also known as glia-derived
nexin (GDN) or serpin E2 [10] and by the two isoforms of
hepatocyte growth factor activator inhibitor-1 (HAI-1),
probably originating from two mRNA splice variants of
HAI-1, here denoted HAI-1A, and HAI-1B [11]. HAI-1B
differs from HAI-1A by a 16-amino acid insertion [12].
Prostasin is part of the matriptase-prostasin proteolytic
cascade regulating terminal epidermal differentiation
[13]. Matriptase is thought to be the first protease in the
cascade due to its ability to auto-activate [14,15] and
because prostasin is activated by a matriptase-catalysed
cleavage [13]. The downstream target for prostasin is
unclear but the matriptase-prostasin cascade eventually
regulate the processing of the differentiation marker filag-
grin [16,17] and is essential for establishment of epider-
mal integrity [17,18]. It has furthermore been shown that
prostasin can activate the epithelial sodium channel
(ENaC) [19] and cleave the epidermal growth factor
receptor [20] but may very well also have other substrates.
Matriptase and prostasin share the same inhibitors, as
both are inhibited by HAI-1A, HAI-1B [11,12], and PN-1
[21]. Using transgenic mice it has been shown that dereg-
ulated matriptase causes carcinogenesis. Even a modest
over-expression of matriptase in the skin of transgenic
mice caused spontaneous squamous cell carcinoma in
70% of the mice [22]. Simultaneous over-expression of
the matriptase inhibitor HAI-1 completely negated the
oncogenic effects of matriptase [22]. Although not known
it is unlikely that the oncogenic properties of matriptase
are exerted via activation of prostasin as prostasin over-
expression has been shown to cause reduced in vitro inva-
siveness in both prostate and mammary cancer cell lines
[23,24] and high prostasin mRNA levels correlates with
longer survival for gastric cancer patients [25].
Prostasin is expressed in most epithelial cells and could
potentially play a role in most types of cancer. Prostasin
has been shown to be down-regulated in gastric cancers
[25] and prostate cancer [26]. The enzymatic activity of
prostasin may be regulated by several mechanisms one of
them being by regulating the mRNA expression levels of
its inhibitors PN-1, HAI-1A, and HAI-1B. Elevated PN-1
levels have been found in pancreatic, breast and oral can-
cers [27-29]. PN-1 does not seem to be a specific inhibitor
for prostasin and matriptase as it also inhibits thrombin,
trypsin, plasmin and plasminogen activators [30-32] and
functions as a neurite growth promoting factor in neurob-
lastoma cells [33]. HAI-1A and HAI-1B are also non spe-
cific inhibitors for prostasin and matriptase as they also
inhibit hepatocyte growth factor activator and trypsin
[12]. No physiological difference between HAI-1A and
HAI-1B has been found. We have previously observed that
the HAI-1 mRNA levels are decreased during colorectal
cancer carcinogenesis in both normal and affected tissue
from individuals with colorectal cancer adenomas and
carcinomas as compared to healthy individuals using an
assay that does not differentiate between HAI-1A and
HAI-1B [34]. Likewise HAI-1 has been shown to be down-
regulated in renal cell carcinomas [35] and in gastric and
colorectal cancer [36].
In the present study we have investigated the mRNA levels
of prostasin and its inhibitors PN-1, HAI-1A, and HAI-1B,
during colorectal cancer carcinogenesis in humans.
Methods
Subject population
The KAM cohort (Kolorektal cancer, Arv og Miljø) is based
on the screening group of the Norwegian Colorectal Can-
cer Prevention study (the NORCCAP study) in the county
of Telemark, Norway [37]. Additionally, a series of color-
ectal cancer cases were recruited to the KAM cohort from
routine clinical work at Telemark Hospital in Skien and
Ulleval University Hospital in Oslo. The ID number for
the NORCCAP study at Clinicaltrials.gov is
NCT00119912 [38]. In the NORCCAP study a total of
20,780 men and women, age distribution 50–64 years,
drawn randomly from the population registries in Oslo
(urban) and the county of Telemark (mixed urban and
rural) were invited to have a flexible sigmoidoscopy (FS)
screening examination with or without (1:1) an addi-
tional faecal occult blood test (FOBT). 777 (4%) individ-
uals were excluded according to exclusion criteria [37].
The KAM biobank currently consists of 234 colorectal can-
cer cases, 1044 cases with adenomas (229 high-risk, 762
low-risk and 53 hyperplastic polyps) and 400 controls.
Controls were defined as individuals with normal find-
ings at the time of FS. The KAM study is approved by the
Regional Committee for Medical Research Ethics and the
Norwegian Data Inspectorate. In the present study we
BMC Cancer 2009, 9:201 http://www.biomedcentral.com/1471-2407/9/201
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have analyzed cases with carcinoma (n = 116), cases with
adenoma (n = 106) and controls that were polyp-free at
time of FS (n = 23). Each case was classified according to
the degree of malignancy in the lesion. For individuals
with adenoma a sample of control tissue was collected 30
cm from the anus. Control samples from healthy individ-
uals were taken from individuals, where no adenomas or
carcinomas could be identified with FS. The histology of
the adenomas was examined independently by two his-
topathologists to categorize the degree of dysplasia as
either mild/moderate (n = 93) or severe (n = 13). They
reached consensus in all cases. Cases of dysplasia were
also classified as either low- or high-risk according to the
size and/or differentiation state of the adenoma. A high-
risk adenoma is defined as an adenoma measuring more
than 10 mm in diameter and/or with villous components
or showing severe dysplasia. [37]. The distribution of gen-
der and age among controls and cases with carcinoma or
adenoma of the colon is shown in Table 1.
RT-PCR
Total RNA was purified from tissue as recommended by
the manufacturers using E.Z.N.A. Total RNA Kit II (VWR,
Copenhagen, Denmark). The tissue samples were frozen
in liquid as soon as possible after surgery and were stored
in liquid N2 until RNA purification. RNA purification
included a DNAse treatment. cDNA synthesis was per-
formed on approximately 200 ng RNA per 20 μl using
High-Capacity cDNA Archive Kit (Applied Biosystems,
Denmark). Quantitative RT-PCR for prostasin was per-
formed on the ABI7300 sequence detection system
(Applied Biosystems) in Universal Mastermix (Applied
Biosystems) using 160/100 nM probe and 600/200 nM
primers for prostasin and PN-1, respectively. For detection
of prostasin mRNA, primers and probes were: F, 5'
GGCCTCCACTGCACTGTCA 3'; R,5' AGTTACACGTCT-
CACGACTGATCAG '3'; probe, 5'-FAM-CAGTGAGCCTC-
CTGACGCCCAAG-BHQ-3'. For detection of PN-1 mRNA,
primer and probes were: F, 5' CCTCCATGTTTCTCAT-
ATCTTGCA 3'; R, 5' ACCAGGGAGGCGATGATCT 3';
probe, 5'FAM-AAGCTTCAGCAGCAACAACTGCAAT-
TCTCA-BHQ-3'. Primers were designed within different
exons and with probes covering the exon-exon border to
prevent amplification of genomic DNA. DNA coding for
HAI-1 gives rise to two mRNA's coding for two proteins
where the amino acids sequence differs by 16 residues
[12]. We have previously measured the HAI-1 mRNA
using a probe/primer set that detects both HAI-1A and
HAI-1B. For this study we have designed new sets of
probe/primers specific for either HAI-1A or HAI-1B.
Assays for HAI-1A and HAI-1B were performed using 300
nM probe and 100 nM primers. Primers and probes for
detection of HAI-1A were: F, 5'AGA TCT GCA AGA GTT
TCG TTT ATG G-3'; R, 5'-GGT GCC AGA GCA CAC TGG
AT-3'; probe, 5'-FAM-TGT GCA AGG CCC CTC CAT GGA
A-BHQ-1-3'. Primers and probes for detection of HAI-1B
were: F, 5'-ATC TGC AAG AGT TTC GTT TAT GGA-3'; R, 5'-
GGT GCC AGA GCA CAC TGG AT-3'; probe, FAM-CCT
TTG AGA GGC AGC TC-MGBNFQ. HAI-1A and HAI-1B
probes were obtained from Applied Biosystems. β-actin
primers and probes were obtained as a pre-developed
assay (cat. no. 4310881E). All other primers and probes
were obtained from TAG Copenhagen (Denmark). In a
validation experiment using a control sample, a dilution
series was produced and assayed for prostasin, PN-1, HAI-
1A, HAI-1B and β-actin as described for the comparative Ct
method [39]. When Ct values were plotted against log
dilution it was shown that the assays are quantitative over
a range of 256-fold dilution and that the PCR reactions
have similar efficiencies provided that a threshold of 0.02
is used for prostasin and 0.2 is used for PN-1, HAI-1A,
HAI-1B, and β-actin. The threshold is a fixed fluorescence
signal level above the baseline and the Ct value of a sam-
ple is determined as the fractional cycle number where the
sample's fluorescence signal exceeds the threshold. Prosta-
sin, PN-1, HAI-1A, HAI-1B, and β-actin were quantified
Table 1: Characteristics of cases and healthy individuals participating in this study
Prostasin Healthy Cases
Adenomas1 Carcinomas
Mild/moderate dysplasia Severe dysplasia
(n = 23) (n = 93) (n = 13) (n = 116)
Men 9 68 7 59
Women 14 25 6 57
Mean age +SD2 56.3 ± 4.6 57.3 ± 3.5 54.8 ± 3.1 68.7 ± 12.4
1The adenomas are divided in groups according to diagnosed degree of dysplasia.
2There are significant differences in age among the four groups of healthy and affected individuals at 95% confidence level (Kruskal-Wallis test).
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separately in triplicates. The average standard deviation
on the triplicates was 14% or less. The standard deviation
on repeated measurements of the same sample (the con-
trol) in separate experiments was 20%, 11%, 14%, and
14% for prostasin, PN-1, HAI-1A and HAI-1B respectively,
indicating the day-to-day variation of the assay. Inde-
pendent PCR reactions of the same samples yielded a cor-
relation coefficient of 0.85 for prostasin and 0.95 for PN-1.
Negative controls (where the RNA was not converted into
cDNA) and positive controls were included in all sets.
Statistical analysis
MiniTab Statistical Software, Release 13.1 Xtra (Minitab
Inc.) and Graph Pad Prism 4 were used for the statistic cal-
culations. The data were not adjusted for gender since the
incidence ratio of colorectal cancer between the genders is
1:1 in Norway [40].
Immunohistochemistry
Tissue specimens were fixed in 4% formalin, paraffin
embedded and processed for routine histology. Tissue sec-
tions were cleared with xylene and rehydrated in a graded
series of alcohols and boiled in T-EG buffer (10 mM Tris,
0.5 mM EDTA, pH = 9) for 20 min for antigen retrieval.
The sections were blocked for 30 min in PBS containing
3% BSA and 0.1% Triton X-100 and then incubated at
4°C overnight with mouse anti-prostasin antibody (BD
Biosciences, cat nr. 612173) (0.02 μg/μl) and goat anti-
hHAI-1 (RD System, cat nr. AF1048, diluted 1:1000). The
slides were washed 3 times for 5 min with 3% BSA in PBS
and 0.1% Triton X-100 and incubated at room tempera-
ture for 45 min with the secondary antibody Alexa fluor
555 donkey anti-mouse and Alexa fluor 488 donkey anti-
goat. Afterwards, tissue sections were washed 3 times for 5
min with 3% BSA in PBS and 0.1% Triton X-100, followed
by 4 times in PBS and finally mounted with DAPI H-1500
(Vector Laboratories Inc.). The sections were examined for
the localization of prostasin subjected to laser conven-
tional fluorescence microscopy. Sections where the pri-
mary antibodies were omitted served as controls.
Results
Expression of prostasin and PN-1 mRNA during 
carcinogenesis
The mRNA levels of prostasin and PN-1 were measured in
colon tissue samples from healthy individuals (n = 23),
individuals with mild/moderate dysplasia (n = 93), indi-
viduals with severe dysplasia (n = 13), and individuals
with colorectal cancer (n = 116) by real-time RT-PCR.
From individuals with dysplasia a sample of histologically
normal tissue was used as well. From individuals with
colorectal cancer two sample of histologically normal tis-
sue from the surgically removed tissue were used. Ole
sample was obtained as far away from the cancer tissue as
possible (normal distant) and another sample obtained
immediately adjacent to the cancer tissue (normal adja-
cent). A good correlation between the mRNA and protein
levels for both prostasin [26] and PN-1 [41] has previously
been shown. The mRNA levels of prostasin, PN-1, HAI-1A
and HAI-1B were normalised to the mRNA level of β-actin.
The range and the interquartile range of mRNA levels of
prostasin normalised to β-actin are shown in Figure 1.
When the prostasin mRNA level of healthy individuals was
compared to normal or affected tissue from individuals
with dysplasia or colorectal cancer no significant differ-
ence could be observed (Figure 1 and Table 2). However,
the prostasin mRNA level of all adenomas and carcinomas
combined was statistically significantly lower than the
level in tissue from healthy individuals (p < 0.05). There
was also a significant difference when normal and affected
tissue from the same individual were compared for indi-
viduals with mild/moderate dysplasia (p < 0.001), severe
dysplasia (p < 0.01), and for colorectal cancer both com-
pared to the normal distant (p < 0.05) and to the normal
adjacent sample (p < 0.01). This shows that the prostasin
mRNA level is slightly but significant lower in mild/mod-
erate dysplasia, severe dysplasia and colorectal cancer tis-
sue as compared to normal tissue.
The range and the interquartile range of mRNA levels of
PN-1 normalised to β-actin are shown in Figure 2. The PN-
1 mRNA level showed an increase with increasing tumour
grade in dysplastic and cancerous tissues whereas the nor-
mal tissue was not affected. A significant almost 3-fold
increase (p < 0.001) of PN-1 mRNA was found in carcino-
mas as compared to corresponding tissues in healthy indi-
viduals (Table 2 and Figure 1). Comparing the level of PN-
1 in dysplastic and cancerous tissue with the correspond-
ing normal tissue from the same individual, significant
higher levels were encountered in mild/moderate dyspla-
sia (p < 0.001), severe dysplasia (p < 0.05) and in carcino-
mas both when compared to the normal distant sample
and with normal adjacent sample (p < 0.001), (Table 2).
In addition we found a significantly higher level of PN-1
mRNA when comparing affected tissue from mild/moder-
ate and severe dysplasia combined (all adenomas) with
carcinomas (p < 0.001) using a one-way ANOVA and
Tukey's post test. The PN-1 mRNA levels thus seem to be
upregulated both at the transition from normal tissue to
mild/moderate dysplasia and then again at the transition
between dysplasia and cancer tissue whereas normal tis-
sue is not affected.
Colorectal cancer can be staged according to Dukes' stage
A-D where D is the most advanced and metastatic stage.
Among the carcinomas in this study 23 carcinomas were
designated as Dukes'stage A, 47 carcinomas as stage B, 39
carcinomas as stage C and none of the samples were clas-
sified as stage D. No tendency and no significant differ-
ence (one-way ANOVA and Tukey's post test for paired
comparison) were seen when comparing the prostasin and
BMC Cancer 2009, 9:201 http://www.biomedcentral.com/1471-2407/9/201
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PN-1 mRNA levels with the designated Dukes'stages. Like-
wise the adenomas were classified as either low-risk (n =
14) or high-risk (n = 91) adenomas using the criteria
described in material and methods. No significant differ-
ence in the mRNA levels of either prostasin or PN-1 was
seen when comparing high-risk and low-risk adenomas
(one-way ANOVA and Tukey's post test for paired com-
parison). When the prostasin mRNA level in normal tissue
from either healthy individuals or individuals with dys-
plasia or colorectal cancer was plotted against age we were
unable to detect any age-related change in the prostasin
mRNA level (n = 245, age range 26–88) whereas the PN-1
mRNA level showed a slight increase with higher age. We
were unable to detect any gender-related differences in the
prostasin or PN-1 mRNA expression levels.
Expression of HAI-1A and HAI-1B during carcinogenesis
It is possible that prostasin activity is regulated by modu-
lation of the ratio between HAI-1A and HAI-1B as it is not
clear whether the two inhibitors have the same kinetic
properties. The two HAI-1 transcripts differ by the coding
region for 16 amino acids. We have previously shown that
HAI-1 is significantly down-regulated in both normal and
affected tissue from individuals with adenomas and carci-
nomas [34]. In the present study we have investigated a
subset of the cohort using two quantitative RT-PCR assays
specific for HAI-1A and HAI-1B respectively. mRNA levels
for HAI-1A and HAI-1B were determined in colon tissue
samples from healthy individuals (n = 14), in healthy and
affected tissue from individuals with mild/moderate dys-
plasia (n = 19) and in healthy and tumour tissue from
patients with colorectal cancer (n = 24). Figure 3 shows
the range and interquartile range of mRNA levels of HAI-
1A, HAI-1B and the radio of HAI-1A/HAI-1B normalised
to β-actin. The levels of HAI-1A and HAI-1B mRNA found
are virtually identical in all tissues examined with the lev-
els of HAI-1 found previously [34]. Both HAI-1A and HAI-
1B are thus progressively down-regulated with increasing
tumour grade. We thus found no statistically significant
difference between the ratios of HAI-1A/HAI-1B in the dif-
ferent tissues tested. These data suggest that there is no
regulation in the splicing of the HAI-1 transcript during
colorectal cancer carcinogenesis.
Table 2: Prostasin mRNA levels in normal and affected tissues.
Variable mRNA level in normal tissue 
Mean (SD)
Pa mRNA level in adenomas/
carcinomas Mean (SD)
Pa Pb
Prostasin
Healthy individuals 0.96 (0.29)
Mild/moderate 1.10 (0.38) NS 0.62 (0.24) NS <0.001
Severe 1.08 (0.46) NS 0.73 (0.50) NS <0.01
Carcinoma distant adjacent 0.85 (0.65) NS 0.61 (0.60) NS <0.05
0.90 (0.76) NS <0.01
All adenomas and carcinomas 0.96 (0.61) NS 0.62 (0.48) <0.05 ND
PN-1
Healthy individual 0.022 (0.030)
Mild/moderate 0.015 (0.017) NS 0.041 (0.028) NS <0.001
Severe 0.010 (0.003) NS 0.033 (0.031) NS <0.05
Carcinoma distant adjacent 0.028 (0.027) NS 0.063 (0.060) <0.001 <0.001
0.025 (0.018) NS <0.001
The mRNA levels were normalised to β-actin mRNA levels.
NS = not significant
ND = not determined
p value for the comparison to the expression levels in healthy individuals using a one-way ANOVA and Tukey's post test for paired comparisons.
a) p value for the comparison to the expression levels in healthy individuals using a one-way ANOVA and Tukey's post test for paired comparisons.
b) p value for the comparison of the expression levels in normal and affected tissue from the same individual using a paired t-test
BMC Cancer 2009, 9:201 http://www.biomedcentral.com/1471-2407/9/201
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Localization of prostasin and HAI-1 by 
immunohistochemistry
Normal and cancerous tissues from five colorectal cancer
patients were analysed to investigate the sub-cellular
localization of prostasin and HAI-1. Formalin-fixed paraf-
fin-embedded tissue sections were immunohistochemi-
cally co-stained for prostasin and HAI-I. In normal
colorectal tissue, prostasin was detected mainly on the
apical plasma membrane – with only minor staining of
the basolateral plasma membrane (Figure 4A and 4D).
HAI-1 was found mainly on the basolateral plasma mem-
brane mostly not co-localizing with prostasin (Figure 4B
and 4D). This is consistent with previous findings which
showing that prostasin is located primarily on the apical
plasma membrane [23], and mostly secreted from the api-
cal side of polarized epithelial cells [42]. Likewise previ-
ous findings show that HAI-1 is located primarily on the
basolateral plasma membrane of a range of polarized epi-
thelial cells [43-46]. In some colorectal cancer tissue spec-
imens we found a similar polarized apical staining of
prostasin and basolateral staining of HAI-1 as seen in his-
tologically normal tissue (Figure 4E, F, G, and 4H). In
contrast prostasin and HAI-1 were co-localizing in other
colorectal cancer tissue specimens all along the cell
periphery suggesting that the polarization of the cells has
been lost during carcinogenesis (Figure 4L, J, K, and 4L).
Discussion
In the present study we have determined the mRNA levels
of prostasin, PN-1, HAI-1A and HAI-1B during colorectal
cancer carcinogenesis. It has previously been shown that
over-expression of prostasin in mammary and prostate
cancer cells reduces the invasive properties of cancer cells
[23,24] and that high prostasin expression in gastric
tumours is associated with longer survival [25]. It could
thus be speculated that the transition from severe dyspla-
sia to cancer is accompanied by a transcriptional decrease
in prostasin expression and/or a down-regulation of pros-
tasin activity via up regulation of one or more enzymatic
inhibitors of prostasin. In the present study we found
modest but significantly lower levels of prostasin mRNA in
mild/moderate dysplasia, severe dysplasia and colorectal
cancer tissues combined as compared to corresponding
normal tissues from healthy individuals. In a previous
study a similar minor but significant down-regulation was
seen when comparing normal and affected tissue from
gastric cancer patients [25]. Our results do not show any
transcriptional down-regulation of prostasin accompany-
ing the transition between severe dysplasia and colorectal
cancer. However, the mRNA levels of the inhibitor of
prostasin, PN-1 increase at both the transition between
normal tissue and mild/moderate dysplasia and again at
the transition between severe dysplasia and colorectal
cancer.
For PN-1 to be a physiologically relevant inhibitor of
prostasin it is required that PN-1 and prostasin have phys-
ical access to each other. PN-1 belongs to the serpin family
of secretory proteins. We have previously shown that five
other members of the serpin family are secreted to both
The levels of prostasin mRNA were determined by real-time RT-PCR from healthy individuals (N), individuals with mild/moder-ate dysplasia (M/M), severe dysplasia (S) or carcinom s (C)Figure 1
The levels of prostasin mRNA were determined by real-time RT-PCR from healthy individuals (N), individuals 
with mild/moderate dysplasia (M/M), severe dysplasia (S) or carcinomas (C). Both normal (grey bars) and affected 
(white bars) tissues were examined from each individual. From colorectal cancer patients one sample of histological normal tis-
sue was taken as far away from the colorectal cancer tissue as allowed by the surgically removed tissue (normal distant, here 
designated ND) and one sample of histological normal tissue was taken immediately adjacent to the colorectal cancer tissue 
(normal adjacent here designated NA). mRNA levels were normalised to the β-actin mRNA level. The box shows the inter-
quartile range, the whiskers the range and the median is indicated by a vertical line.
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the apical and the basolateral side of the polarized epithe-
lial cell line, MDCK, albeit at different ratios [47]. Similar
results were obtained for the Caco-2 cell line, derived
from a human colonic adenocarcinoma (Vogel et al.,
unpublished results). There are therefore no indications
that PN-1 in the extracellular fluid has restricted access to
plasma membrane-bound prostasin. Consequently, it is
possible that PN-1 plays an important role in down-regu-
lating the enzymatic activity of prostasin in cancer tissue
resulting in more invasive cell behaviour.
Prostasin is inhibited not only by PN-1 but also by HAI-
1A and HAI-1B. We have previously shown that the level
The levels of protease nexin-1 (PN-1) mRNA were determined by real-time RT-PCR from healthy individuals (N), individualswith mild/moderate dysplasia (M/M), severe dysplasia (S) or carcinomas (C)Figure 2
The levels of protease nexin-1 (PN-1) mRNA were 
determined by real-time RT-PCR from healthy indi-
viduals (N), individuals with mild/moderate dysplasia 
(M/M), severe dysplasia (S) or carcinomas (C). Sym-
bols and group designations are the same as in Figure 1. 
mRNA levels were normalised to the β-actin mRNA level. 
The box shows the interquartile range, the whiskers the 
range and the median is indicated by a vertical line.
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The levels of HAI-1A and HAI-1B mRNA were determined by real-time RT-PCR from healthy individuals (N), individuals with mild/moderate dysplasia (M/M) or carcinomas (C)Figure 3
The levels of HAI-1A and HAI-1B mRNA were deter-
mined by real-time RT-PCR from healthy individuals 
(N), individuals with mild/moderate dysplasia (M/M) 
or carcinomas (C). Symbols and group designations are 
the same as in Figure 1. mRNA levels were normalised to the 
β-actin mRNA level. The box shows the interquartile range, 
the whiskers the range and the median is indicated by a verti-
cal line.
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of HAI-1 mRNA is decreased by 3-fold during colorectal
cancer carcinogenesis using an assay that does not distin-
guish between HAI-1A and HAI-1B [34]. In the present
study we have shown that HAI-1A and HAI-1B have
expression patterns virtually identical and indistinguisha-
ble from the expression pattern of HAI-1 previously found
[34] and that the ratio of HAI-1A/HAI-1B remains the
same in all tissues investigated during colorectal cancer
carcinogenesis. Therefore, the splicing of HAI-1 mRNA is
not regulated during carcinogenesis. In the present study
we found limited co-localization of prostasin and HAI-1
in normal tissue, as HAI-1 is located mainly on the baso-
lateral plasma membrane and prostasin is located on the
apical plasma membrane. This probably does not mean
that their interactions is limited due to physical separation
as we have previously shown that HAI-1 is transcytosed
from the basolateral plasma membrane to the apical
plasma membrane [43]. It is thus possible that HAI-1
interacts with prostasin at the apical plasma membrane.
The enzymatic activity of prostasin is influenced both by
the levels of PN-1, HAI-1A and HAI-1B and probably also
by the expression levels of other as yet undiscovered
inhibitors of prostasin. The relative physiological impor-
tance of PN-1, HAI-1A and HAI-1B as inhibitors of prosta-
sin is at present unclear. PN-1 is an inhibitor of not only
prostasin, but also of uPA, tPA, thrombin, plasmin,
trypsin [48] and matriptase [21] and it forms an essen-
tially non-reversible binding to its target protease like
most other serpins [49]. Apart from physical accessibili-
ties, the relative abundances of other target proteases may
become an important issue as an abundant target for PN-
1 may "quench" a large amount of PN-1 by forming a
non-reversible complex with it. However, the co-purifica-
tion of prostasin in complex with PN-1 [49] suggests that
PN-1, at least to some degree plays a role as an inhibitor
of prostasin in vivo. Likewise prostasin-HAI-1B complexes
have been purified from a cell line [11], suggesting that it
is a physiologically relevant inhibitor of prostasin. Further
knowledge about the binding kinetics between the pro-
teases and their inhibitors is needed to clarify the relative
importance of PN-1 and HAI-1 isoforms as inhibitors of
prostasin.
Prostasin and HAI-1 are located on the apical and the basolateral side, respectively in normal tissue and some colorectal cancer tissue pecimens whe as they are co-localized in other colorectal cancer tissu s specimensFig re 4
Prostasin and HAI-1 are located on the apical and the basolateral side, respectively in normal tissue and some 
colorectal cancer tissue specimens whereas they are co-localized in other colorectal cancer tissues specimens. 
Tissue sections of formalin-fixed, paraffin-embedded normal and malignant tissue from colorectal cancer patients was immuno-
histochemically stained for prostasin (A, E, I) and HAI-1(B, F, J). Histological normal colorectal tissue from a cancer patient 
(upper panel, A, B, C and D) and two examples of colorectal cancer tissue are shown (middle and lower panel). Nuclei were 
visualized by DAPI staining (C, G, and K).
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Conclusion
Proteases have for a long time been thought to play an
important role in the growth of cells both during tissue
remodelling and invasive growth. However, the action of
proteases may be regulated not necessarily by the expres-
sion of the protease but by regulating the expression of its
inhibitors. Our data shows that elevated mRNA levels for
prostasins inhibitor, PN-1, coincides with acquisition of
malignant properties, whereas the mRNA level of prostasin
is relative stable during colorectal cancer carcinogenesis.
However, further investigations are necessary to under-
stand the role of prostasin, PN-1, HAI-1A and HAI-1B for
invasive growth and malignant progression.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
LV conceived the idea of the study. EHK designed the
cohort and collected the samples. LV and EHK extracted
the RNA. LV and JB designed and validated primers and
probes and performed the statistical analyses. JS-P per-
formed the immunohistochemistry. IMBL evaluated the
tissue sections. JS-P, SF and LV prepared the figures. KMT
and EKH administrated the KAM study. LV and JS-P wrote
the first draft of the manuscript. All authors helped inter-
pret the results, writing the manuscript and read and
approved the final version.
Acknowledgements
We thank Christel Halberg for kind technical help and assistance.
This work was supported by The Norwegian Cancer Society, Telemark 
University College, the Norwegian Colorectal Cancer Prevention (NORC-
CAP) study, Eastern Norway Regional Health Authority, The cluster of Cell 
Biology at the University of Copenhagen and The Lundbeck Foundation.
References
1. Lopez-Otin C, Matrisian LM: Tumour micro environment –
Opinion – Emerging roles of proteases in tumour suppres-
sion.  Nature Reviews Cancer 2007, 7:800-808.
2. Balbin M, Fueyo A, Tester AM, Pendas AM, Pitiot AS, Astudillo A,
Overall CM, Shapiro SD, Lopez-Otin C: Loss of collagenase-2 con-
fers increased skin tumor susceptibility to male mice.  Nature
Genetics 2003, 35:252-257.
3. McCawley LJ, Crawford HC, King LE, Mudgett J, Matrisian LM: A pro-
tective role for matrix metalloproteinase-3 in squamous cell
carcinoma.  Cancer Research 2004, 64:6965-6972.
4. Overall CM, Kleifeld O: Tumour microenvironment – Opinion
– Validating matrix metalloproteinases as drug targets and
anti-targets for cancer therapy.  Nature Reviews Cancer 2006,
6:227-239.
5. Yu JX, Chao L, Chao J: Molecular cloning, tissue-specific expres-
sion, and cellular localization of human prostasin mRNA.  J
Biol Chem 1995, 270:13483-13489.
6. Vallet V, Chraibi A, Gaeggeler HP, Horisberger JD, Rossier BC: An
epithelial serine protease activates the amiloride-sensitive
sodium channel.  Nature 1997, 389:607-610.
7. Verghese GM, Gutknecht MF, Caughey GH: Prostasin regulates
epithelial monolayer function: cell-specific Gpld1-mediated
secretion and functional role for GPI anchor.  American Journal
of Physiology-Cell Physiology 2006, 291:C1258-C1270.
8. Vassalli JD, Huarte J, Bosco D, Sappino AP, Sappino N, Velardi A,
Wohlwend A, Erno H, Monard D, Belin D: Protease-nexin I as an
androgen-dependent secretory product of the murine semi-
nal vesicle.  EMBO J 1993, 12:1871-1878.
9. Chen LM, Zhang XC, Chai KX: Regulation of prostasin expres-
sion and function in the prostate.  Prostate 2004, 59:1-12.
10. Knauer DJ, Thompson JA, Cunningham DD: Protease Nexins –
Cell-Secreted Proteins That Mediate the Binding, Internali-
zation, and Degradation of Regulatory Serine Proteases.
Journal of Cellular Physiology 1983, 117:385-396.
11. Fan B, Wu TD, Li W, Kirchhofer D: Identification of hepatocyte
growth factor activator inhibitor-1B as a potential physiolog-
ical inhibitor of prostasin.  J Biol Chem 2005, 280:34513-34520.
12. Kirchhofer D, Peek M, Li W, Stamos J, Eigenbrot C, Kadkhodayan S,
Elliott JM, Corpuz RT, Lazarus RA, Moran P: Tissue expression,
protease specificity, and Kunitz domain functions of hepato-
cyte growth factor activator inhibitor-1B (HAI-1B), a new
splice variant of HAI-1.  J Biol Chem 2003, 278:36341-36349.
13. Netzel-Arnett S, Currie BM, Szabo R, Lin CY, Chen LM, Chai KX,
Antalis TM, Bugge TH, List K: Evidence for a matriptase-prosta-
sin proteolytic cascade regulating terminal epidermal differ-
entiation.  Journal of Biological Chemistry 2006, 281:32941-32945.
14. Oberst MD, Chen LYL, Kiyomiya KI, Williams CA, Lee MS, Johnson
MD, Dickson RB, Lin CY: HAI-1 regulates activation and
expression of matriptase, a membrane-bound serine pro-
tease.  American Journal of Physiology-Cell Physiology 2005,
289:C462-C470.
15. Oberst MD, Williams CA, Dickson RB, Johnson MD, Lin CY: The
activation of matriptase requires its noncatalytic domains,
serine protease domain, and its cognate inhibitor.  J Biol Chem
2003, 278:26773-26779.
16. List K, Szabo R, Wertz PW, Segre J, Haudenschild CC, Kim SY, Bugge
TH: Loss of proteolytically processed filaggrin caused by epi-
dermal deletion of Matriptase/MT-SP1.  J Cell Biol 2003,
163:901-910.
17. Leyvraz C, Charles RP, Rubera I, Guitard M, Rotman S, Breiden B,
Sandhoff K, Hummler E: The epidermal barrier function is
dependent on the serine protease CAP1/Prss8.  Journal of Cell
Biology 2005, 170:487-496.
18. List K, Haudenschild CC, Szabo R, Chen W, Wahl SM, Swaim W,
Engelholm LH, Behrendt N, Bugge TH: Matriptase/MT-SP1 is
required for postnatal survival, epidermal barrier function,
hair follicle development, and thymic homeostasis.  Oncogene
2002, 21:3765-3779.
19. Bruns JB, Carattino MD, Sheng S, Maarouf AB, Weisz OA, Pilewski JM,
Hughey RP, Kleyman TR: Epithelial Na+ channels are fully acti-
vated by furin- and prostasin-dependent release of an inhibi-
tory peptide from the gamma-subunit.  J Biol Chem 2007,
282:6153-6160.
20. Chen MQ, Fu YY, Lin CY, Chen LM, Chai KX: Prostasin induces
protease-dependent and independent molecular changes in
the human prostate carcinoma cell line PC-3.  Biochimica et Bio-
physica Acta-Molecular Cell Research 2007, 1773:1133-1140.
21. Myerburg MM, McKenna EE, Luke CJ, Frizzell RA, Kleyman TR,
Pilewski JM: Prostasin expression is regulated by airway sur-
face liquid volume and is increased in cystic fibrosis.  American
Journal of Physiology-Lung Cellular and Molecular Physiology 2008,
294:L932-L941.
22. List K, Szabo R, Molinolo A, Sriuranpong V, Redeye V, Murdock T,
Burke B, Nielsen BS, Gutkind SJ, Bugge TH: Deregulated
matriptase causes ras-independent multistage carcinogene-
sis and promotes ras-mediated malignant transformation.
Genes & Development 2005, 19:1934-1950.
23. Chen LM, Hodge GB, Guarda LA, Welch JL, Greenberg NM, Chai KX:
Down-regulation of prostasin serine protease: a potential
invasion suppressor in prostate cancer.  Prostate 2001,
48:93-103.
24. Chen LM, Chai KX: Prostasin serine protease inhibits breast
cancer Invasiveness and is transcriptionally regulated by pro-
moter DNA methylation.  International Journal of Cancer 2002,
97:323-329.
25. Sakashita K, Mimori K, Tanaka F, Tahara K, Inoue H, Sawada T, Ohira
M, Hirakawa K, Mori M: Clinical Significance of Low Expression
of Prostasin mRNA in Human Gastric Cancer.  Journal of Surgi-
cal Oncology 2008, 98:559-564.
26. Takahashi S, Suzuki S, Inaguma S, Ikeda Y, Cho YM, Hayashi N, Inoue
T, Sugimura Y, Nishiyama N, Fujita T, Chao J, Ushijima T, Shirai T:
Down-regulated expression of prostasin in high-grade or
Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2009, 9:201 http://www.biomedcentral.com/1471-2407/9/201
Page 10 of 10
(page number not for citation purposes)
hormone-refractory human prostate cancers.  Prostate 2003,
54:187-193.
27. Gao S, Krogdahl A, Sorensen JA, Kousted TM, Dabelsteen E,
Andreasen PA: Overexpression of protease nexin-1 mRNA
and protein in oral squamous cell carcinomas.  Oral Oncol 2007,
44:309-313.
28. Candia BJ, Hines WC, Heaphy CM, Griffith JK, Orlando RA: Pro-
tease nexin-1 expression is altered in human breast cancer.
Cancer Cell Int 2006, 6:16.
29. Buchholz M, Biebl A, Neesse A, Wagner M, Iwamura T, Leder G,
Adler G, Gress TM: SERPINE2 (protease nexin I) promotes
extracellular matrix production and local invasion of pancre-
atic tumors in vivo.  Cancer Res 2003, 63:4945-4951.
30. Rao JS, Kahler CB, Baker JB, Festoff BW: Protease nexin I, a ser-
pin, inhibits plasminogen-dependent degradation of muscle
extracellular matrix.  Muscle Nerve 1989, 12:640-646.
31. Stone SR, Hermans JM: Inhibitory mechanism of serpins. Inter-
action of thrombin with antithrombin and protease nexin 1.
Biochemistry 1995, 34:5164-5172.
32. Eaton DL, Baker JB: Evidence that a variety of cultured cells
secrete protease nexin and produce a distinct cytoplasmic
serine protease-binding factor.  J Cell Physiol 1983, 117:175-182.
33. Gurwitz D, Cunningham DD: Neurite outgrowth activity of pro-
tease nexin-1 on neuroblastoma cells requires thrombin
inhibition.  J Cell Physiol 1990, 142:155-162.
34. Vogel LK, Saebo M, Skjelbred CF, Abell K, Pedersen ED, Vogel U,
Kure EH: The ratio of Matriptase/HAI-1 mRNA is higher in
colorectal cancer adenomas and carcinomas than corre-
sponding tissue from control individuals.  Bmc Cancer 2006,
6:176-183.
35. Yamauchi M, Kataoka H, Itoh H, Seguchi T, Hasui Y, Osada Y: Hepa-
tocyte growth factor activator inhibitor types 1 and 2 are
expressed by tubular epithelium in kidney and downregu-
lated in renal cell carcinoma.  Journal of Urology 2004,
171:890-896.
36. Zeng L, Cao J, Zhang X: Expression of serine protease SNC19/
matriptase and its inhibitor hepatocyte growth factor activa-
tor inhibitor type 1 in normal and malignant tissues of gas-
trointestinal tract.  World Journal of Gastroenterology 2005,
11:6202-6207.
37. Gondal G, Grotmol T, Hofstad B, Bretthauer M, Eide TJ, Hoff G: The
Norwegian Colorectal Cancer Prevention (NORCCAP)
screening study.  Scandinavian Journal of Gastroenterology 2003,
38:635-642.
38. Clinical Trials  2007 [http://clinicaltrials.gov].
39. Johnson MR, Wang KS, Smith JB, Heslin MJ, Diasio RB: Quantitation
of dihydropyrimidine dehydrogenase expression by real-
time reverse transcription polymerase chain reaction.  Analyt-
ical Biochemistry 2000, 278:175-184.
40. The Cancer Registry of Norway: Cancer in Norway 2001.  Oslo:
InfoPrint as, 2004 .
41. Gao S, Krogdahl A, Sorensen JA, Kousted TM, Dabelsteen E,
Andreasen PA: Overexpression of protease nexin-1 mRNA
and protein in oral squamous cell carcinomas.  Oral Oncol 2007,
44:309-313.
42. Verghese GM, Gutknecht MF, Caughey GH: Prostasin regulates
epithelial monolayer function: cell-specific Gpld1-mediated
secretion and functional role for GPI anchor.  American Journal
of Physiology-Cell Physiology 2006, 291:C1258-C1270.
43. Godiksen S, Selzer-Plon J, Pedersen EDK, Abell K, Rasmussen HB,
Szabo R, Bugge TH, Vogel LK: Hepatocyte growth factor activa-
tor inhibitor-1 has a complex subcellular itinerary.  Biochemical
Journal 2008, 413:251-259.
44. Shimomura T, Denda K, Kitamura A, Kawaguchi T, Kito M, Kondo J,
Kagaya S, Qin L, Takata H, Miyazawa K, Kitamura N: Hepatocyte
growth factor activator inhibitor, a novel Kunitz-type serine
protease inhibitor.  Journal of Biological Chemistry 1997,
272:6370-6376.
45. Oberst M, Anders J, Xie B, Singh B, Ossandon M, Johnson M, Dickson
RB, Lin CY: Matriptase and HAI-1 are expressed by normal
and malignant epithelial cells in vitro and in vivo.  Am J Pathol
2001, 158:1301-1311.
46. Kataoka H, Suganuma T, Shimomura T, Itoh H, Kitamura N,
Nabeshima K, Koono M: Distribution of hepatocyte growth fac-
tor activator inhibitor type 1 (HAI-1) in human tissues. Cel-
lular surface localization of HAI-1 in simple columnar
epithelium and its modulated expression in injured and
regenerative tissues.  J Histochem Cytochem 1999, 47:673-682.
47. Vogel LK, Larsen JE: Apical and non-polarized secretion of ser-
pins from MDCK cells.  FEBS Lett 2000, 473:297-302.
48. Irving JA, Pike RN, Lesk AM, Whisstock JC: Phylogeny of the ser-
pin superfamily: Implications of patterns of amino acid con-
servation for structure and function.  Genome Research 2000,
10:1845-1864.
49. Chen LM, Zhang X, Chai KX: Regulation of prostasin expression
and function in the prostate.  Prostate 2004, 59:1-12.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/9/201/pre
pub
